Ethanol Infusion Into the Vein of Marshall for Atrial Fibrillation: Clinical Efficacy and Technical Limitations
Clinical Cardiology · 2026-07 · 49 (7)
DOI: 10.1002/clc.70398 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Cardiology, online erschienen am 29.06.2026. Verfasst von Xuepeng Zheng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, China-Japan Union Hospital of Jilin University, Jilin Provincial Molecular Biology Research Center for Precision Medicine o…. Hauptthemen laut MEDLINE: Atrial Fibrillation, Ethanol, Catheter Ablation, Heart Rate. Die Arbeit nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology of Jilin Province, Health Science Research Talent Programme of Jilin Province.
Abstract (Originalsprache)
Background
Despite advancements in radiofrequency ablation (RFCA) technology and strategy, the long‐term rhythm outcomes of persistent atrial fibrillation (PeAF) remain suboptimal. Since the vein of Marshall (VOM) is situated within the mitral isthmus (MI) area and covers local neural innervation and fiber networks, its pathophysiological role in mediating and maintaining atrial fibrillation (AF) and causing arrhythmia recurrence has garnered increasing attention. Hypothesis Ethanol infusion into the vein of Marshall (EIVOM) may complement RFCA by delivering anatomically targeted chemical injury along the VOM course, thereby facilitating contiguous MI lesion formation and durable MI block.
Methods
We performed a narrative review of mechanistic, procedural, and clinical evidence regarding EIVOM in AF ablation, with emphasis on MI block, rhythm outcomes, technical limitations, complications, and its potential role in pulsed field ablation (PFA)‐based workflows.
Results
Available evidence indicates that EIVOM facilitates durable MI block by targeting VOM‐related epicardial connections and may improve rhythm outcomes when combined with RFCA in selected PeAF ablation strategies. Its clinical application is influenced by procedural and anatomical factors, while safety considerations and its potential complementary role in PFA‐based workflows remain important areas for further evaluation.
Conclusions
EIVOM is a promising adjunct to RFCA, particularly for facilitating durable MI block and reducing residual epicardial conduction. Further standardized multicenter studies are needed to refine patient selection, procedural integration, safety optimization, and its role in contemporary AF ablation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, China-Japan Union Hospital of Jilin University, Jilin Provincial Molecular Biology Research Center for Precision Medicine of Major Cardiovascular Disease, Changchun, China.
- Department of Ultrasonography, China-Japan Union Hospital of Jilin University, Changchun, China.
ORCID-Profile: Hongliang Yang, Daoyuan Si, Yuquan He
Förderung
- Science and Technology of Jilin Province
- Health Science Research Talent Programme of Jilin Province
Zitieren
APA
Zheng, X., Yang, H., Sun, H., Yu, M., Ni, L., Si, D., & He, Y. (2026). Ethanol Infusion Into the Vein of Marshall for Atrial Fibrillation: Clinical Efficacy and Technical Limitations. Clinical Cardiology, 49(7). https://doi.org/10.1002/clc.70398
Vancouver
Zheng X, Yang H, Sun H, Yu M, Ni L, Si D, et al. Ethanol Infusion Into the Vein of Marshall for Atrial Fibrillation: Clinical Efficacy and Technical Limitations. Clinical Cardiology. 2026;49(7). doi:10.1002/clc.70398
BibTeX
@article{Zheng2026,
author = {Zheng, Xuepeng and Yang, Hongliang and Sun, Huan and Yu, Ming and Ni, Lujia and Si, Daoyuan and He, Yuquan},
title = {Ethanol Infusion Into the Vein of Marshall for Atrial Fibrillation: Clinical Efficacy and Technical Limitations},
journal = {Clinical Cardiology},
year = {2026},
volume = {49},
number = {7},
doi = {10.1002/clc.70398}
}
EUVIMED